Illinois court rejects dismissal of AbbVie patent case

The US District Court for the Northern District of Illinois has refused to dismiss a lawsuit from AbbVie which alleges Icelandic pharmaceutical company Alvotech infringed patents related to its arthritis drug Humira.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

9 March 2023 The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.

Biotechnology

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

21 December 2021 AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.

Americas

AbbVie, Abbott fight bid to force FTC discovery disclosure

6 April 2021 Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Illinois court rejects dismissal of AbbVie patent case

More on this story

Editor's picks

Editor's picks

More features